{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:56:10Z","timestamp":1790873770094,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Fund Project of Education Department of Yunnan Province","award":["NO.2024J0277"],"award-info":[{"award-number":["NO.2024J0277"]}]},{"name":"Kunming Health Science and Technology \"Thousand Project\" Talents Project","award":["NO.2021-SW (reserve)-08"],"award-info":[{"award-number":["NO.2021-SW (reserve)-08"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for type 2 diabetes mellitus (T2DM) due to their multifaceted benefits, including glycemic control and cardiovascular protection. However, variations in prescribing practices and potential adverse drug events (ADEs) necessitate standardized prescription review protocols to ensure medication safety and efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aimed to develop and implement GLP-1RA prescription review rules through a multidisciplinary information pharmacist team, evaluate their impact on prescription rationality, and identify ADE risk signals using real-world data, thereby promoting rational clinical medication use and ensuring patient safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A multidisciplinary information pharmacist team was established at a tertiary hospital to develop GLP-1RA prescription review protocols. China-approved GLP-1RA formulations and their clinical parameters were systematically reviewed to establish standardized prescribing criteria, including indications, dosing, and safety considerations. Adverse drug events were analyzed using FDA Adverse Event Reporting System data (2018\u20132023) to identify risk patterns. A dual review system integrating prospective prescription screening and retrospective evaluation was implemented. The intervention\u2019s efficacy was evaluated by comparing prescription approval rates pre- (2022) and post-implementation (2023).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The GLP-1RA audit rules represented by liraglutide and semaglutide were successfully created, as well as their potential adverse event signals were successfully obtained. The process of prescription review and medication monitoring enabled them to be put into clinical practice. After the rules were put in place in 2023, the pass rates of GLP-1RA prescriptions significantly improved, and the rationalization of these prescriptions was also notably enhanced compared to the same period in 2022 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Standardized GLP-1RA review rules enhanced prescription rationality and ADE risk awareness, demonstrating the value of information pharmacists in optimizing clinical decision-making. This model is scalable for other high-risk medications, promoting safer drug use and pharmacist-led innovation in healthcare.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12913-025-13377-2","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:32:39Z","timestamp":1759314759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Information pharmacists assist in the construction of GLP-1RA prescription review rules in a tertiary hospital in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Li","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Duanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feilong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"issue":"24","key":"13377_CR1","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"issue":"8","key":"13377_CR2","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/dom.14418","volume":"23","author":"A Daly","year":"2021","unstructured":"Daly A, Hovorka R. Technology in the management of type 2 diabetes: present status and future prospects. Diabetes Obes Metab. 2021;23(8):1722\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"13377_CR3","doi-asserted-by":"publisher","unstructured":"Weinberg Sibony R, Segev O, Dor S, Raz I. Drug therapies for diabetes. Int J Mol Sci. 2023;24(24):17147. https:\/\/doi.org\/10.3390\/ijms242417147.","DOI":"10.3390\/ijms242417147"},{"issue":"7","key":"13377_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/1753-0407.13434","volume":"15","author":"Z Bloomgarden","year":"2023","unstructured":"Bloomgarden Z. A diabetes update. J Diabetes. 2023;15(7):542\u20134.","journal-title":"J Diabetes"},{"issue":"9","key":"13377_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41574-019-0234-2","volume":"15","author":"C Greenhill","year":"2019","unstructured":"Greenhill C. T2DM treatment trial results. Nat Rev Endocrinol. 2019;15(9):499.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"13377_CR6","first-page":"393","volume":"18","author":"S Starling","year":"2022","unstructured":"Starling S. Targeting hyperglucagonaemia in T2DM. Nat Rev Endocrinol. 2022;18(7):393.","journal-title":"Nat Rev Endocrinol"},{"key":"13377_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72\u2013130.","journal-title":"Mol Metab"},{"key":"13377_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022;57:101351.","journal-title":"Mol Metab"},{"issue":"35","key":"13377_CR9","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/eurheartj\/ehaa174","volume":"41","author":"N Marx","year":"2020","unstructured":"Marx N. Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. Eur Heart J. 2020;41(35):3359\u201362.","journal-title":"Eur Heart J"},{"key":"13377_CR10","doi-asserted-by":"publisher","unstructured":"Lohia S, Siwy J, Mavrogeorgis E, Eder S, Th\u00f6ni S, Mayer G, et al. Exploratory study analyzing the urinary peptidome of T2DM patients suggests changes in ECM but also inflammatory and metabolic pathways following GLP-1R agonist treatment. Int J Mol Sci. 2023;24(17):13540. https:\/\/doi.org\/10.3390\/ijms241713540.","DOI":"10.3390\/ijms241713540"},{"issue":"1","key":"13377_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","volume":"22","author":"P Gourdy","year":"2023","unstructured":"Gourdy P, Darmon P, Dievart F, Halimi JM, Guerci B. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). Cardiovasc Diabetol. 2023;22(1):79.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"13377_CR12","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11154-023-09825-1","volume":"24","author":"J Andraos","year":"2023","unstructured":"Andraos J, Muhar H, Smith SR. Beyond glycemia: comparing tirzepatide to GLP-1 analogues. Rev Endocr Metab Disord. 2023;24(6):1089\u2013101.","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"13377_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13663","volume":"25","author":"RM Goldenberg","year":"2024","unstructured":"Goldenberg RM, Gilbert JD, Manjoo P, Pedersen SD, Woo VC, Lovshin JA. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists. Obes Rev. 2024;25(3):e13663.","journal-title":"Obes Rev"},{"key":"13377_CR14","doi-asserted-by":"publisher","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","volume":"149","author":"P Karakasis","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists Orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023;149:155710.","journal-title":"Metabolism"},{"issue":"2","key":"13377_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","volume":"12","author":"K Arvanitakis","year":"2023","unstructured":"Arvanitakis K, Koufakis T, Popovic D, Maltese G, Mustafa O, Doumas M, Giouleme O, Kotsa K, Germanidis G. GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use. Curr Obes Rep. 2023;12(2):61\u201374.","journal-title":"Curr Obes Rep"},{"issue":"12","key":"13377_CR16","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","volume":"29","author":"L Leggio","year":"2023","unstructured":"Leggio L, Hendershot CS, Farokhnia M, Fink-Jensen A, Klausen MK, Schacht JP, Simmons WK. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29(12):2993\u20135.","journal-title":"Nat Med"},{"key":"13377_CR17","unstructured":"National Health Commission of the PRC. Notice on the Issuance of prescription review Standards for Medical Institutions. 2018. [http:\/\/www.nhc.gov.cn\/yzygj. Accessed 6 Sept 2023.]."},{"issue":"2","key":"13377_CR18","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.2337\/dc18-1893","volume":"42","author":"T Wang","year":"2019","unstructured":"Wang T, Lu W, Tang H, Buse JB, St\u00fcrmer T, Gower EW. Assessing the association between GLP-1 receptor agonist use and diabetic retinopathy through the FDA adverse event reporting system. Diabetes Care. 2019;42(2):e21-3.","journal-title":"Diabetes Care"},{"issue":"18","key":"13377_CR19","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.21037\/atm-21-4162","volume":"9","author":"Z Zhao","year":"2021","unstructured":"Zhao Z, Tang Y, Hu Y, Zhu H, Chen X, Zhao B. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Ann Transl Med. 2021;9(18):1482.","journal-title":"Ann Transl Med"},{"issue":"11","key":"13377_CR20","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm R, Bulin C, Waetzig V, Cascorbi I, Klein HJ, Herdegen T. Pharmacovigilance-based drug repurposing: the search for inverse signals via openvigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol. 2021;87(11):4421\u201331.","journal-title":"Br J Clin Pharmacol"},{"key":"13377_CR21","doi-asserted-by":"publisher","first-page":"1226778","DOI":"10.3389\/fphar.2023.1226778","volume":"14","author":"Z Feng","year":"2023","unstructured":"Feng Z, Tong WK, Zhang X, Tang Z. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Front Pharmacol. 2023;14:1226778.","journal-title":"Front Pharmacol"},{"issue":"3","key":"13377_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","volume":"12","author":"Y Mu","year":"2024","unstructured":"Mu Y, Bao X, Eliaschewitz FG, Hansen MR, Kim BT, Koroleva A, et al. Efficacy and safety of once weekly semaglutide 2\u00b74\u00a0mg for weight management in a predominantly East Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2024;12(3):184\u201395.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"13377_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/M20-2470","volume":"173","author":"K Doyle-Delgado","year":"2020","unstructured":"Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American Diabetes Association\u2019s standards of medical care in diabetes clinical guideline. Ann Intern Med. 2020;173(10):813\u201321.","journal-title":"Ann Intern Med"},{"issue":"1","key":"13377_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4158\/CS-2019-0472","volume":"26","author":"AJ Garber","year":"2020","unstructured":"Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013\u20092020 executive summary. Endocr Pract. 2020;26(1):107\u201339.","journal-title":"Endocr Pract"},{"issue":"2","key":"13377_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta CE, Rotem R, Bateman BT, Chodick G, Cohen JM, Furu K, et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern Med. 2024;184(2):144\u201352.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"13377_CR26","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388.","journal-title":"N Engl J Med"},{"issue":"6","key":"13377_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, de Oliveira Costa J, Falster MO, Pearson SA, Mahaffey KW, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024;149(6):450\u201362.","journal-title":"Circulation"},{"issue":"13","key":"13377_CR28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMe2401743","volume":"390","author":"DG Standaert","year":"2024","unstructured":"Standaert DG. GLP-1, Parkinson\u2019s disease, and neuroprotection. N Engl J Med. 2024;390(13):1233\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"13377_CR29","doi-asserted-by":"publisher","first-page":"18290","DOI":"10.1038\/s41598-024-69016-z","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, Su X, Hao Y, Liu J. Cardio metabolic survey i: knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors. Sci Rep. 2024;14(1):18290.","journal-title":"Sci Rep"},{"issue":"3","key":"13377_CR30","doi-asserted-by":"publisher","first-page":"562","DOI":"10.18549\/PharmPract.2015.03.562","volume":"13","author":"TB Dick","year":"2015","unstructured":"Dick TB, Moorman KL, MacDonald EA, Raines AA, Cox KD. Defining and implementing a model for pharmacy resident research projects. Pharm Pract (Granada). 2015;13(3):562.","journal-title":"Pharm Pract (Granada)"},{"issue":"1","key":"13377_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1177\/1078155216677854","volume":"24","author":"V Kletas","year":"2018","unstructured":"Kletas V, de Lemos M. Development of a systematic approach to pharmaceutical industry\u2019s patient assistance programs on accessing unfunded cancer drugs. J Oncol Pharm Pract. 2018;24(1):18\u201321.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"13377_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.sapharm.2022.09.010","volume":"19","author":"A Ogundipe","year":"2023","unstructured":"Ogundipe A, Sim TF, Emmerton L. Health information communication technology evaluation frameworks for pharmacist prescribing: a systematic scoping review. Res Social Adm Pharm. 2023;19(2):218\u201334.","journal-title":"Res Social Adm Pharm"},{"key":"13377_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmedinf.2022.104983","volume":"172","author":"F Ranchon","year":"2023","unstructured":"Ranchon F, Chanoine S, Lambert-Lacroix S, Bosson JL, Moreau-Gaudry A, Bedouch P. Development of artificial intelligence powered apps and tools for clinical pharmacy services: a systematic review. Int J Med Inform. 2023;172:104983.","journal-title":"Int J Med Inform"},{"issue":"11","key":"13377_CR34","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40261-022-01202-1","volume":"42","author":"T Wu","year":"2022","unstructured":"Wu T, Zhang Y, Shi Y, Yu K, Zhao M, Liu S, et al. Safety of glucagon-like peptide-1 receptor agonists: a real-world study based on the US FDA adverse event reporting system database. Clin Drug Investig. 2022;42(11):965\u201375.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"13377_CR35","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11096-023-01556-2","volume":"45","author":"M Cao","year":"2023","unstructured":"Cao M, Pan C, Tian Y, Wang L, Zhao Z, Zhu B. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA adverse event reporting system and literature visualization analysis. Int J Clin Pharm. 2023;45(3):689\u201397.","journal-title":"Int J Clin Pharm"},{"issue":"10","key":"13377_CR36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/17512433.2022.2120468","volume":"15","author":"W Zuo","year":"2022","unstructured":"Zuo W, Sun Y, Liu R, Du L, Yang N, Sun W, et al. Management guideline for the off-label use of medicine in China (2021). Expert Rev Clin Pharmacol. 2022;15(10):1253\u201368.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"13377_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/ejhpharm-2017-001283","volume":"25","author":"Z Zheng","year":"2018","unstructured":"Zheng Z, Zeng Y, Huang H. Pharmacists\u2019 role in off-label drug use in China. Eur J Hosp Pharm. 2018;25(2):116.","journal-title":"Eur J Hosp Pharm"},{"issue":"7","key":"13377_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2146\/ajhp170580","volume":"75","author":"J Chalmers","year":"2018","unstructured":"Chalmers J, Siska M, Le T, Knoer S. Pharmacy informatics in multihospital health systems: opportunities and challenges. Am J Health-Syst Pharm. 2018;75(7):457\u201364.","journal-title":"Am J Health-Syst Pharm"},{"issue":"11","key":"13377_CR39","doi-asserted-by":"publisher","first-page":"e1004133","DOI":"10.1371\/journal.pmed.1004133","volume":"19","author":"S Rodgers","year":"2022","unstructured":"Rodgers S, Taylor AC, Roberts SA, Allen T, Ashcroft DM, Barrett J, Boyd MJ, Elliott RA, Khunti K, Sheikh A, et al. Scaling-up a pharmacist-led information technology intervention (PINCER) to reduce hazardous prescribing in general practices: multiple interrupted time series study. PLoS Med. 2022;19(11):e1004133.","journal-title":"PLoS Med"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13377-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13377-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:32:41Z","timestamp":1759314761000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13377-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13377"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13377-2","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The information on prior prescription data involved in this study was obtained from our hospital\u2019s prescription audit management system, and the ADEs data information was obtained from the FAERS database. Ethical approval was not considered necessary given the use of the identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1276"}}